[A19-104] Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59
Last updated 06.03.2020
Project no.:
A19-104
Commission:
Commission awarded on 10.12.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Indication:
Adults with paroxysmal nocturnal haemoglobinuria (PNH)
Result of dossier assessment:
Conclusion of dossier assessment A19-59 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-59 | Ravulizumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.